The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index; 38 of the 56 sources its claims cite were checked for support.
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
Open accessPublished version of a preprint
Abstract
Purpose: In many cancers, nivolumab in combination with ipilimumab improves response rates compared with either agent alone, but the combination has not been evaluated in childhood cancer. We conducted a phase I/II trial of nivolumab plus ipilimumab in children and young adults with recurrent/refractory solid tumors. Patients and Methods: ADVL1412, Part C assessed safety of nivolumab plus ipilimumab at two dose levels (DL): DL1 1 mg/kg of each drug and DL2 3 mg/kg nivolumab plus 1 mg/kg ipilimumab. Part D evaluated response at the recommended phase II dose (RP2D) in Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Part E tested DL3 (1 mg/kg nivolumab plus 3 mg/kg ipilimumab) in Ewing sarcoma and rhabdomyosarcoma. Tumor response was measured using RECIST v1.1. Pharmacokinetics and PD-L1 expression on archival tissues were assessed. Results: Fifty-five eligible patients enrolled. Based on safety, tolerability, and similar drug exposure to the same doses administered in adults, DL2 was defined as the pediatric RP2D. Among 41 patients treated at the RP2D, 2 patients experienced dose-limiting toxicities during cycle 1, and 4 patients experienced toxicities beyond that period. Two patients had clinically significant sustained partial responses (1 rhabdomyosarcoma, 1 Ewing sarcoma) and 4 had stable disease. Among 8 patients treated at DL3, 3 dose-limiting toxicities (DLT) occurred, all immune-related adverse events; no objective responses were observed. Conclusions: The RP2D of nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) is well tolerated in children and young adults with solid tumors and shows some clinical activity. Increased dose of ipilimumab (3 mg/kg) plus nivolumab (1 mg/kg) was associated with increased toxicity without clinical benefit.
Overview
CoChat Summary
TL;DR
In children and young adults with relapsed/refractory solid tumors, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg was defined as the pediatric RP2D and showed tolerable toxicity with limited clinical activity. A higher ipilimumab dose (3 mg/kg with nivolumab 1 mg/kg) was associated with increased immune-related toxicity and no objective responses.
Key findings
- Fifty-five eligible patients enrolled; 53 were evaluable for DLT. DL2 (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg) was defined as the pediatric RP2D based on safety, tolerability, and similar drug exposure to the same doses in adults. Among 41 patients treated at the RP2D, 2 had Cycle 1 DLTs (grade 3 creatinine increase; grade 4 pleural effusion), and additional DLTs beyond Cycle 1 occurred in 2 Part C patients and 4 Part D patients.
- At the RP2D, 2 patients had confirmed partial responses (1 alveolar rhabdomyosarcoma, 1 Ewing sarcoma) and 4 had stable disease (2 rhabdomyosarcoma, 1 myofibroblastic tumor, 1 nasopharyngeal carcinoma). Both responders remained alive without disease progression at 36-month follow-up. No activity was observed in the osteosarcoma cohort.
- Among 8 patients treated at DL3 (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg), 3 DLTs occurred (37.5%), all immune-related adverse events; no objective responses were observed in rhabdomyosarcoma (n=3) or Ewing sarcoma (n=4).
- Of 49 patients with archival tumor tissue evaluable for PD-L1, only 7 (14%) had any PD-L1 staining; there was no clear relationship between PD-L1 expression and clinical response or toxicity.
Methods
- ADVL1412 Parts C–E: Part C was dose finding at DL1 (1 mg/kg nivolumab plus 1 mg/kg ipilimumab) and DL2 (3 mg/kg nivolumab plus 1 mg/kg ipilimumab); Part D tested DL2 in disease-specific expansion cohorts for rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma using a Simon optimal two-stage design; Part E tested DL3 (1 mg/kg nivolumab plus 3 mg/kg ipilimumab) in rhabdomyosarcoma and Ewing sarcoma.
- Treatment was given Day 1 every 21 days for four cycles, followed by single-agent nivolumab 3 mg/kg every 14 days. Response was assessed by RECIST v1.1 with central review; toxicity was graded by CTCAE v5.0; pharmacokinetics and PD-L1 immunohistochemistry on archival tissue were assessed.
- The Simon design assumed a true response rate of 5% versus 25%, with type I error 0.07, power 0.88, and expected sample size of 14 with 60% probability of early termination.
Limitations
- Stated: evaluation was limited to common childhood sarcomas (rhabdomyosarcoma, Ewing sarcoma, osteosarcoma), so performance in other childhood cancer histologies is not addressed; enrollment of very young children was limited; PD-L1 IHC was largely performed on diagnostic specimens, so PD-L1 expression at the time of immune checkpoint therapy is unknown; tumor neoantigen burden could not be evaluated; pre-treatment biopsies and additional correlative studies are needed.
- Evident from the text: this was a single-arm, non-randomized trial with small disease-specific cohorts; Part E was closed early after the DL3 stopping rule was triggered, limiting efficacy assessment; no expansion cohort met response criteria to proceed to stage 2; patients received a median of 2 cycles, which may limit comparisons of toxicity and response with adult regimens.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
22 Valid · 0 Not valid · 5 Not checked · 94 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Single agent CTLA-4 blockade showed no significant antitumor activity in a Phase I trial of children with melanoma or other solid tumors10,11.”
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Introduction
What the sources say
- Supportedcites [10] Merchant, 2016, Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors, Clin Cancer Res source
The Results (Evaluation of clinical activity; page unavailable) report no complete or partial responses by standard RECIST criteria in the pediatric phase I trial. The Discussion says the authors saw no role for single-agent ipilimumab in these pediatric tumors. Some patients had stable disease, so the finding is best understood as a lack of significant objective antitumor activity, not an absence of any clinical benefit. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [11] Geoerger, 2017, Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma, Eur J Cancer source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Relapsed and refractory childhood solid tumors are rarely curable with conventional cytotoxic regimens1,2.”
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Introduction
What the sources say
- Partly supportedcites [1] Smith, 2010, Outcomes for children and adolescents with cancer: challenges for the twenty-first century, J Clin Oncol sourceExperimental — accuracy not yet measured
The Results (page unavailable) say that pediatric solid tumors have shown limited progress and that better use of available cytotoxic agents is unlikely to produce substantial gains. They do not specifically address cure rates for relapsed or refractory solid tumors, so the claim’s patient group and ‘rarely curable’ conclusion are not established by this source. (LLM, conf=0.83)
- Could not verifycites [2] Smith, 2014, Declining childhood and adolescent cancer mortality, Cancer sourceExperimental — accuracy not yet measured
The Introduction says progress was limited for some childhood cancers, and the Discussion says opportunities to improve solid-tumor outcomes are less apparent. Neither passage addresses whether relapsed or refractory childhood solid tumors are rarely curable with conventional cytotoxic regimens. Searches for relapse, cure, and chemotherapy did not establish that claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, consistent single agent activity of PD-1 or PD-L1 blockade in cancers arising in children and young adults has been limited to Hodgkin and non-Hodgkin lymphoma and cancers arising in the context of biallelic mismatch repair6–8,9.”
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Introduction
What the sources say
- Not checked — no full text of the sourcecites [6] Geoerger, 2020, Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial, Lancet Oncol source
- Not checked — no full text of the sourcecites [7] Geoerger, 2020, Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study, Lancet Oncol source
- Not checked — no full text of the sourcecites [8] Bouffet, 2016, Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency, J Clin Oncol source
- Partly supportedcites [9] Davis, 2020, Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial, Lancet Oncol sourceExperimental — accuracy not yet measured
The Discussion (page not provided) reports single-agent nivolumab activity in Hodgkin lymphoma, one response among 10 patients with non-Hodgkin lymphoma, and no activity in the non-lymphoma solid tumours studied. It also reports significant PD-1-blockade responses in children with hypermutant tumours associated with germline mismatch-repair mutations. The claim overstates the evidence for consistent activity across non-Hodgkin lymphoma and for limiting activity to these cancers generally: the trial tested only selected tumour types and did not test all PD-1 or PD-L1 blockers. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Combination ICI regimens are associated with an increased rate and severity of immune related adverse events compared to PD-1/PD-L1 blockade alone, and these appear to be related to the dose of ipilimumab administered.”
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Introduction
What the sources say
- Not checked — no full text of the sourcecites [30] Hodi, 2018, Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial, Lancet Oncol source
- Supportedcites [31] Lebbé, 2019, Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial, J Clin Oncol source
The Introduction (page not available) reports grade 3–4 treatment-related adverse events in 55% of patients receiving nivolumab plus ipilimumab versus 16% receiving nivolumab alone in the cited CheckMate 067 trial. The Results > Safety section also finds fewer grade 3–5 events with the lower-ipilimumab-dose combination. The direct monotherapy comparison is for PD-1 blockade in advanced melanoma, not PD-L1 blockade. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mean trough concentrations of ipilimumab (1mg/kg) were maintained above the 6 μg/ml concentration that was found to maximally inhibit CTLA-4 binding to its CD80 and CD86 ligands with the 1 mg/kg dose35.”
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Discussion
What the sources say
- Partly supportedcites [35] Sheng, 2017, Clinical pharmacology considerations for the development of immune checkpoint inhibitors, J Clin Pharmacol sourceExperimental — accuracy not yet measured
Table 1 (Conclusions; page unavailable) reports ipilimumab trough levels exceeding 3 μg/mL at 3 and 10 mg/kg, so it supports the general point that ipilimumab trough concentrations were assessed. It does not report troughs above 6 μg/mL at 1 mg/kg or identify 6 μg/mL as the concentration maximally inhibiting CTLA-4 binding to CD80 and CD86. The table’s 6 μg/mL trough statement is in the atezolizumab column. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
51 more claims · 7 with their cited sources checked
Create a free account to see all 121 claims and to verify the 2 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 37
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“a dimensional response (PR) was described in a patient with Ewing sarcoma with the combination of nivolumab and ipilimumab, but it only lasted 3 months. 26”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For pediatric studies that include biomarker testing as part of the evaluation of a PD-(L)1 inhibitor, the reported PD-L1 positive expression rates range from 14% to 35%, with the highest expression rates reported in study cohorts of lymphoid malignancies (Hodgkin lymphoma and non-Hodgkin lymphoma) (6, 8, 10).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, to date, no objective responses have been reported with any ICI combination regimen in young children (age <10 years) with a solid tumor (8, 17).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several phase I/II studies of ICI monotherapies (ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab) and combination regimens (nivolumab plus ipilimumab) have been conducted in pediatric populations, but limited antitumor activity has been observed, with objective response rates ranging from 0% to 5.9% for children with a solid tumor, including sarcoma.”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The safety profile observed for patients receiving the durvalumab/tremelimumab regimen appears comparable to that for the previous dual ICI regimen evaluated in children, with a similar overall incidence and pattern of AEs reported in both studies during the study treatment period; in this study, the incidence of grade 3–4 AEs possibly attributed to study treatment across both treatment phases was”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Discussion
“we observed diarrhea in only 4 patients and none more than Grade 2.”
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Results > Safety and Tolerability
“Two additional subjects on Part E experienced cycle 2 DLTs that were immune-related AEs (irAE; Grade 4 diarrhea, elevated AST/ALT, hyperthyroidism)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Results > Pharmacokinetics
“A mean trough concentration of 3.9±1.4 mg/ml (n=32) ipilumumab was reached after the first 1 mg/kg dose of ipilimumab (n = 32).”
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Results > Pharmacokinetics
“The trough concentration increased to 6.0±2.3 ug/ml after the second dose (n = 12)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Eighteen specimens demonstrated PD-L1+ immune cells that were neither lymphocytes nor macrophages, 5 demonstrated only PD-L1+ macrophages, 7 demonstrated only PD-L1+ lymphocytes, and 12 demonstrated both.”
§ A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children’s Oncology Group Study ADVL1412 > Results > Response
Reported 36 · recomputed 42
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Cited by
Ryan, T. D., Bates, J. E., Kinahan, K. E., Leger, K. J., Mulrooney, D. A., Narayan, H. K., Ness, K. K., Okwuosa, T. M., Rainusso, N. C., Steinberger, J., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001308 · Cited by 75
Cottrell, T. R., Lotze, M. T., Ali, A., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 69
Emerging therapies in Ewing sarcoma
Strauss, S. J., Berlanga, P., & McCabe, M. G. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001048 · Cited by 55
Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 67
Meyers, P. A., Federman, N. C., Daw, N. C., Anderson, P. M., Davis, L. E., Kim, A., Macy, M. E., Pietrofeso, A., Ratan, R., Riedel, R. F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00020 · Cited by 41
Metadata
- Authors
- Davis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L.
- Affiliations
- Stanford Medicine (US)
- St. Jude Children's Research Hospital (US)
- Mayo Clinic (US)
- Children's Oncology Group (US)
- Baylor College of Medicine (US)
- Harvard University (US)
- University of Minnesota (US)
- Corresponding author
- Davis, Kara L.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2022-10-03
- Volume
- 28
- Issue
- 23
- Pages
- 5088-5097
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC10597535
- OpenAlex
- W4300688643
- Cited by
- 75
- References
- 47
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 18 · 2023: 9 · 2022: 1
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Bristol-Myers Squibb (CA209-070)
- National Institutes of Health (CA228823, 5P30CA124435, P30 CA015083)
- Cookies for Kids' Cancer Foundation (NA)
- Parker Institute for Cancer Immunotherapy
- Virginia and D.K. Ludwig Fund for Cancer Research
- Stanford Maternal and Child Health Research Institute
- National Institute of General Medical Sciences (T32GM 08685)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- nivolumab, ipilimumab, immune checkpoint inhibitors, combination immunotherapy, pediatric solid tumors, relapsed/refractory cancer, children and young adults, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, dose-limiting toxicity, immune-related adverse events, PD-L1 expression, pharmacokinetics, recommended phase 2 dose
- MeSH terms
- Ipilimumab, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Child, Humans, Neoplasm Recurrence, Local, Rhabdomyosarcoma, Sarcoma, Ewing, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-2164
- The paper
- Davis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022). A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-2164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.